Developing Extrachromosomal Gene Expression Vector Technologies: An Overview
Author:
Wade-Martins Richard
Reference78 articles.
1. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E, Radford, I, Villeval, JL, Fraser, CC, Cavazzana-Calvo, M et al. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255–256. 2. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P, Lim, A, Osborne, CS, Pawliuk, R, Morillon, E et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419. 3. Lufino MM, Edser PA, Wade-Martins R. (2008) Advances in High-capacity Extrachromosomal Vector Technology: Episomal Maintenance, Vector Delivery, and Transgene Expression. Mol Ther. 16(9):1525–38. 4. Lindahl, T, Adams, A, Bjursell, G, Bornkamm, GW, Kaschka-Dierich, C and Jehn, U. (1976) Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol 102:511–530. 5. Yates, J, Warren, N, Reisman, D and Sugden, B. (1984) A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 81:3806–3810.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|